Patents/Assignees

Arog Pharmaceuticals, Inc.

12 patents in portfolio

US12534764utility2026
Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated Mutations
0 cites
US12486256utility2025
Crystal Forms of Crenolanib and Methods of Use Thereof
0 cites
US12404555utility2025
Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated Mutations
0 cites
US12383549utility2025
Combination Therapy of Crenolanib and Apoptosis Pathway Agents for the Treatment of Proliferative Disorders
0 cites
US12295948utility2025
Crenolanib for Treating FLT3 Mutated Proliferative Disorders Relapsed/refractory to Prior Treatment
0 cites
US12171757utility2024
Crenolanib for Treating FLT3 Mutated Proliferative Disorders
0 cites
US11969420utility2024
Combination Therapy of Crenolanib and Apoptosis Pathway Agents for the Treatment of Proliferative Disorders
0 cites
US11857546utility2024
Crenolanib for Treating FLT3 Mutated Proliferative Disorders Relapsed/refractory to Prior Treatment
0 cites
US11738017utility2023
Method of Inhibiting Constitutively Active Phosphorylated FLT3 Kinase
0 cites
US11713310utility2023
Crystal Forms of Crenolanib and Methods of Use Thereof
0 cites
US11642340utility2023
Method of Inhibiting Mutant C-KIT
0 cites
US11602533utility2023
Crenolanib Combination Therapy
0 cites